Phage activity against Staphylococcus aureus is impaired in plasma and synovial fluid.
Détails
Télécharger: 37875544_BIB_183FA57EA7AC.pdf (2802.30 [Ko])
Etat: Public
Version: Final published version
Licence: CC BY 4.0
Etat: Public
Version: Final published version
Licence: CC BY 4.0
ID Serval
serval:BIB_183FA57EA7AC
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Phage activity against Staphylococcus aureus is impaired in plasma and synovial fluid.
Périodique
Scientific reports
ISSN
2045-2322 (Electronic)
ISSN-L
2045-2322
Statut éditorial
Publié
Date de publication
24/10/2023
Peer-reviewed
Oui
Volume
13
Numéro
1
Pages
18204
Langue
anglais
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't
Publication Status: epublish
Publication Status: epublish
Résumé
S. aureus is a pathogen that frequently causes severe morbidity and phage therapy is being discussed as an alternative to antibiotics for the treatment of S. aureus infections. In this in vitro and animal study, we demonstrated that the activity of anti-staphylococcal phages is severely impaired in 0.5% plasma or synovial fluid. Despite phage replication in these matrices, lysis of the bacteria was slower than phage propagation, and no reduction of the bacterial population was observed. The inhibition of the phages associated with a reduction in phage adsorption, quantified to 99% at 10% plasma. S. aureus is known to bind multiple coagulation factors, resulting in the formation of aggregates and blood clots that might protect the bacterium from the phages. Here, we show that purified fibrinogen at a sub-physiological concentration of 0.4 mg/ml is sufficient to impair phage activity. In contrast, dissolution of the clots by tissue plasminogen activator (tPA) partially restored phage activity. Consistent with these in vitro findings, phage treatment did not reduce bacterial burdens in a neutropenic mouse S. aureus thigh infection model. In summary, phage treatment of S. aureus infections inside the body may be fundamentally challenging, and more investigation is needed prior to proceeding to in-human trials.
Mots-clé
Humans, Animals, Mice, Staphylococcus aureus/physiology, Tissue Plasminogen Activator, Synovial Fluid, Staphylococcal Infections/therapy, Staphylococcal Infections/microbiology, Staphylococcus Phages/physiology, Anti-Bacterial Agents
Pubmed
Web of science
Open Access
Oui
Création de la notice
30/10/2023 12:51
Dernière modification de la notice
25/01/2024 7:31